PURPOSE: We compared the effect of a beta 3-adrenoceptor (AR) agonist with that of beta 1 and beta 2-AR agonists on the urethra and bladder in the dog and rat. MATERIALS AND METHODS: In an in vitro experiment we studied the relaxant effect of subtype selective beta-AR agonists in canine and rat urethral and bladder smooth muscle using an organ bath method. In addition, in urethane anesthetized rats we measured urethral pressure and bladder pressure simultaneously in the presence of the beta 3-agonist CL316243 and the beta 2-agonist procaterol in 4 or 5 animals. RESULTS: In the dog the relaxing effects of isoprenaline in the distal urethra were about half those seen in the detrusor and trigone. The rank order of relaxing potency was CL316243 > dobutamine (beta 1-agonist) = procaterol in detrusor and trigone but procaterol > dobutamine = CL316243 in the prostatic and distal urethra. In rat urethral smooth muscle in vitro the corresponding order was procaterol > CL316243 > dobutamine and the maximal relaxation to each agonist was about half that seen in the bladder. In the anesthetized rat procaterol clearly decreased urethral pressure but CL316243 produced only a slight decrease at its maximal dose, although each agonists clearly reduced bladder pressure. The beta 2-antagonist ICI-118551 counteracted the decrease in urethral and bladder pressure induced by procaterol. CONCLUSIONS: In rats and dogs a selective beta 3-AR agonist can decrease bladder pressure without affecting urethral pressure.
PURPOSE: We compared the effect of a beta 3-adrenoceptor (AR) agonist with that of beta 1 and beta 2-AR agonists on the urethra and bladder in the dog and rat. MATERIALS AND METHODS: In an in vitro experiment we studied the relaxant effect of subtype selective beta-AR agonists in canine and rat urethral and bladder smooth muscle using an organ bath method. In addition, in urethane anesthetized rats we measured urethral pressure and bladder pressure simultaneously in the presence of the beta 3-agonist CL316243 and the beta 2-agonist procaterol in 4 or 5 animals. RESULTS: In the dog the relaxing effects of isoprenaline in the distal urethra were about half those seen in the detrusor and trigone. The rank order of relaxing potency was CL316243 > dobutamine (beta 1-agonist) = procaterol in detrusor and trigone but procaterol > dobutamine = CL316243 in the prostatic and distal urethra. In rat urethral smooth muscle in vitro the corresponding order was procaterol > CL316243 > dobutamine and the maximal relaxation to each agonist was about half that seen in the bladder. In the anesthetized rat procaterol clearly decreased urethral pressure but CL316243 produced only a slight decrease at its maximal dose, although each agonists clearly reduced bladder pressure. The beta 2-antagonist ICI-118551 counteracted the decrease in urethral and bladder pressure induced by procaterol. CONCLUSIONS: In rats and dogs a selective beta 3-AR agonist can decrease bladder pressure without affecting urethral pressure.
Authors: Akira Furuta; Yasuyuki Suzuki; Koji Asano; William C de Groat; Shin Egawa; Naoki Yoshimura Journal: Int Urogynecol J Date: 2011-03-29 Impact factor: 2.894
Authors: F Aura Kullmann; Brian J Limberg; Debra E Artim; Mansi Shah; Thomas R Downs; Dan Contract; John Wos; Jan S Rosenbaum; William C de Groat Journal: J Pharmacol Exp Ther Date: 2009-06-10 Impact factor: 4.030
Authors: E C Alexandre; L R Kiguti; F B Calmasini; F H Silva; K P da Silva; R Ferreira; C A Ribeiro; F Z Mónica; A S Pupo; E Antunes Journal: Br J Pharmacol Date: 2016-01-15 Impact factor: 8.739
Authors: Stefan Propping; Kristina Lorenz; Martin C Michel; Manfred P Wirth; Ursula Ravens Journal: Front Pharmacol Date: 2016-05-09 Impact factor: 5.810